To explore the mechanism of hPRDX5 in inhibiting the growth of pancreatic cancer, tumor and pancreatic tissues and blood samples were collected to compare the proportion of important immune cells (including CD3+T, CD4+T, CD8+T, MDSC, NK cells, etc.)in the treated and control groups after 14 days of administration. This evidence concerns the gene CD4 and familial pancreatic carcinoma.